IMPACT Therapeutics Inc is a China-based company primarily engaged in the research, development, and commercialization of pharmaceutical products. The Company is principally engaged in the research and development of synthetic lethality-based precision anti-cancer therapies. The Company's product pipeline is primarily composed of Senaparib, as well as novel antibody-drug conjugates (ADCs) and degrader candidates. The Company distributes its products within the domestic market and to overseas markets.

Employees

Sector

Biotechnology & Medical Research

Calendar

08-31 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
28/08/26	HK$15.61	-0.57%	645,280
27/08/26	HK$15.70	+9.33%	856,600
26/08/26	HK$14.36	+1.63%	481,000
25/08/26	HK$14.13	+4.51%	377,893
24/08/26	HK$13.52	+0.45%	505,321

Delayed Quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

13.40CNY

Average target price

28.52CNY

Spread / Average Target

+112.87%

Consensus

Net sales - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. 09:08:33 28/08/2026 BST			5-day change	1st Jan Change
15.61 ^HKD	-0.57%		+15.97%	-

08-24	IMPACT Therapeutics to Join Hang Seng Composite Index	MT
08-12	Impact Therapeutics Announces IMP2794 as A Preclinical Candidate, A Highly Kat6a-Specific PROTAC from Its Proprietary Targeted Protein Degradation Platform	CI

Market Cap	3.7B 4.31B 550M 474M 444M 406M 764M 52.55B 766M 5.27B 2.06B 26.53B 2.06B 2.02B 87.96B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	2.86B 3.33B 425M 366M 343M 313M 590M 40.59B 592M 4.07B 1.59B 20.49B 1.59B 1.56B 67.93B	EV / Sales 2026 *	9.94x	EV / Sales 2027 *	2.56x
Free-Float	53.13%	Yield 2026 *	-	Yield 2027 *	-

08-24	IMPACT Therapeutics to Join Hang Seng Composite Index	MT
08-12	Impact Therapeutics Announces IMP2794 as A Preclinical Candidate, A Highly Kat6a-Specific PROTAC from Its Proprietary Targeted Protein Degradation Platform	CI
08-11	IMPACT Therapeutics, Inc. Provides Preliminary Consolidated Earnings Guidance for the Six Months Ended 30 June 2026	CI
07-31	IMPACT Therapeutics, Inc and Pharmanovia Enter Exclusive License Agreement For Senaparib In Europe, Middle East And North Africa, Australia And New Zealand	CI
07-27	IMPACT Therapeutics, Inc Announces IMP3201 As A Preclinical Candidate, A First-In-Class CEACAM5-Targeted Dual-Payload ADC	CI
07-27	Impact Therapeutics Nominates Preclinical Candidate for GI Cancers	MT
07-20	Impact Therapeutics Announces Clinical Data for Senaparib, IMP4297, and IMP1707 Accepted for Poster Presentation at 2026 ESMO Congress	CI
06-08	Impact Therapeutics Nets HK$120 Million From Full Exercise of IPO Overallotment Option	MT
06-01	Impact Therapeutics, Inc Presents Phase 1/2 Clinical Data for Imp1734 At 2026 Asco Annual Meeting	CI
05-13	Hong Kong Stocks Eke Out Gains; Metis TechBio, Impact Therapeutics Shine on Debut	MT
05-13	Impact Therapeutics Jumps 77% in Hong Kong Trading Debut	MT
05-12	Impact Therapeutics Nets HK$759.5 Million From Hong Kong IPO Ahead of Debut	MT
05-12	IMPACT Therapeutics, Inc has completed an IPO in the amount of HKD 843.7377 million.	CI

1 day	-0.57%
1 week	+15.97%
Current month	+17.99%
1 month	+42.56%
3 months	-58.02%

IMPACT Therapeutics, Inc Share Price

Stocks

7630

CNE100007LG4

Biotechnology & Medical Research

Valuation : IMPACT Therapeutics, Inc

Chart: IMPACT Therapeutics, Inc

Latest news : IMPACT Therapeutics, Inc

Press Releases : IMPACT Therapeutics, Inc

Quotes and Performance

Price Extremes

Managers and Directors : IMPACT Therapeutics, Inc

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Net sales - Rate of surprise

1 week	12.76	16.78
1 month	11.28	16.78
Current year	10.31	47.98
1 year	10.31	47.98
3 years	10.31	47.98
5 years	10.31	47.98
10 years	10.31	47.98

Manager	Title	Age	Since
Sui Xiong Cai CEO	Chief Executive Officer	69	31/05/2014
Hui Jun Deng DFI	Director of Finance/CFO	51	30/04/2024
Yan Hua Xu CTO	Chief Tech/Sci/R&D Officer	44	31/12/2024

Director	Title	Age	Since
Ye Tian BRD	Director/Board Member	69	31/05/2014
Sui Xiong Cai BRD	Director/Board Member	69	31/05/2014
Ning Ma BRD	Director/Board Member	44	28/02/2025

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMPACT THERAPEUTICS, INC	-0.57%	+15.97%	-	-	553M
LONZA GROUP AG	-0.78%	-1.42%	+2.49%	+22.78%	51.14B
REVOLUTION MEDICINES, INC.	-6.00%	-0.75%	+442.41%	+544.39%	47.4B
IQVIA HOLDINGS INC.	-0.24%	+0.74%	+38.69%	+18.02%	43.19B
BEONE MEDICINES AG	-1.55%	-2.07%	+23.08%	+81.47%	42.35B
CELLTRION, INC.	-0.31%	-0.83%	+16.15%	+51.42%	33.23B
MEDPACE HOLDINGS, INC.	-1.79%	-3.24%	+27.00%	+129.56%	17.07B
ASCENDIS PHARMA A/S	-0.58%	-2.12%	-	-	16.38B
EUROFINS SCIENTIFIC SE	-0.88%	-0.66%	+11.60%	+27.75%	14.76B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.66%	-1.25%	+78.59%	+46.66%	14.15B
Average	-1.44%	+2.98%	+80.00%	+115.26%	28.02B
Weighted average by Cap.	-1.74%	+0.41%	+98.85%	+137.44%

	2026 *	2027 *
Net sales	288M 335M 42.74M 36.83M 34.53M 31.52M 59.38M 4.08B 59.57M 410M 160M 2.06B 160M 157M 6.84B	941M 1.1B 140M 121M 113M 103M 194M 13.37B 195M 1.34B 523M 6.75B 525M 514M 22.38B
Net income	-	-
Net Debt	-842M -982M -125M -108M -101M -92.33M -174M -11.97B -174M -1.2B -468M -6.04B -470M -460M -20.03B	-1.29B -1.5B -191M -165M -155M -141M -266M -18.29B -267M -1.83B -716M -9.23B -718M -703M -30.61B